Cereno Scientific’s patent protection for drug candidate CS1 expands in Mexico through its second patent family
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s second patent family has obtained a granted patent in Mexico. This strengthens and broadens the intellectual property right (IPR) for Cereno’s Phase II drug candidate CS1 which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“We are building a strong intellectual property rights position for CS1. This is an important part of our efforts to protect our innovations and strengthen the commercial positioning of the drug candidate,” said Sten R. Sörensen, CEO at Cereno. CS1’s